Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer

BACKGROUND: Response rates to single agent immune checkpoint blockade in unselected pretreated HER2−negative metastatic breast cancer (MBC) are low. However, they may be augmented when combined with chemotherapy. METHODS: We conducted a single-arm, phase II study of patients with triple negative (TN...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Immunother Cancer
Главные авторы: Shah, Ami N, Flaum, Lisa, Helenowski, Irene, Santa-Maria, Cesar A, Jain, Sarika, Rademaker, Alfred, Nelson, Valerie, Tsarwhas, Dean, Cristofanilli, Massimo, Gradishar, William
Формат: Artigo
Язык:Inglês
Опубликовано: BMJ Publishing Group 2020
Предметы:
Clinical/Translational Cancer Immunotherapy
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7057426/
https://ncbi.nlm.nih.gov/pubmed/32060053
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2019-000173
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы